Treatment, Medication & Supplement Directory
A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.
Named profile Palladia (Toceranib): Approved Canine Mast Cell Tumor Targeted TherapyRepresentative category illustration – no product packaging is shown.Palladia (Toceranib): Approved Canine Mast Cell Tumor Targeted Therapy
Palladia is an FDA-approved prescription veterinary tyrosine kinase inhibitor for treatment of Patnaik grade II or III recurrent canine cutaneous mast cell tumors, with or without regional lymph-node…
Read more
Named profile Laverdia (Verdinexor): FDA-Approved Oral Therapy for Canine LymphomaRepresentative category illustration – no product packaging is shown.Laverdia (Verdinexor): FDA-Approved Oral Therapy for Canine Lymphoma
Verdinexor is an oral prescription antineoplastic for certain dogs with lymphoma. FDA announced full approval in January 2026 after the product's earlier conditional-approval pathway; publication should use the…
Read more
Prednisone in Canine Cancer Care: A Timing and Safety Discussion
Prednisone is a prescription corticosteroid used in several veterinary cancer contexts, including components of lymphoma protocols and selected palliative plans. Its purpose, timing and taper must be defined…
Read more
Cyclophosphamide in Cancer Protocols: Bladder and Marrow Safety
Cyclophosphamide is an alkylating chemotherapy used in selected veterinary protocols, with blood-count, urinary, gastrointestinal, and household-safety considerations.
Read more
Chlorambucil: Oral Chemotherapy Is Still Hazardous Medicine
Chlorambucil is an oral alkylating chemotherapy used in selected slow-growing blood cancers and other protocols, with cumulative marrow and handling considerations.
Read more
Melphalan in Veterinary Oncology: Cumulative Marrow-Risk Discussion
Melphalan is an alkylating antineoplastic medicine used in selected veterinary cancers and requires individualized blood-count, gastrointestinal, and handling plans.
Read more
Methotrexate in Veterinary Oncology: Interaction and Organ-Safety Review
Methotrexate is a folate-antagonist antimetabolite with selected veterinary uses and clinically important marrow, gastrointestinal, liver, lung, and interaction considerations.
Read more
Metronomic Chemotherapy: Goal, Evidence, and Handling Boundary
Metronomic therapy uses regularly scheduled cytotoxic medication in selected plans; it remains prescription hazardous-drug treatment and is not simply gentle chemotherapy.
Read more
Tyrosine Kinase Inhibitors: A Class-Level Monitoring Framework
Tyrosine kinase inhibitors are not one interchangeable drug class; target profile, label, evidence, dosing, monitoring, and adverse effects differ by product and patient.
Read more
Imatinib in Canine Mast Cell Tumor Care: Extra-Label Evidence Review
Imatinib has published canine mast cell tumor experience but is not interchangeable with veterinary-labeled TKIs and requires specialist, legal, formulation, and evidence review.
Read more
Named profile Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell TumorsRepresentative category illustration – no product packaging is shown.Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell Tumors
Masitinib is an oral canine TKI with an EMA veterinary authorization for a defined mast cell tumor setting; the current regional label governs eligibility and monitoring.
Read more
Antibiotic Use in Immunocompromised Oncology Patients
Cancer or chemotherapy can increase infection concern, but fever, low cell counts, wounds, diarrhea, and urinary signs do not justify automatic or leftover antibiotic use.
Read more